BioMotiv announces immuno-oncology startup with New Zealand university
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutré.
BioMotiv, a Cleveland, Ohio-based drug development accelerator associated with The Harrington Project, and a university in New Zealand have announced the formation of an immuno-oncology startup that will develop a suite of cancer vaccines. SapVax, based on intellectual property licensed from the University of Auckland in New Zealand, will develop the vaccines based on a “self-adjuvanting peptide platform technology.”
Click here to read the complete article, and read more in the related news release.
Originally published January 18, 2017.
Leave a Reply